Maternal and neonatal outcomes with the use of long acting, compared to intermediate acting basal insulin (NPH) for managing diabetes during pregnancy: a systematic review and meta-analysis
Background To assess the impact of long-acting insulin analogues, compared to intermediate acting neutral protamine Hagedron (NPH), on maternal, perinatal and neonatal outcomes. Methods Studies for inclusion in the review were identified using a structured search strategy in PubMed, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) database. Studies that were randomized controlled trials or observational in design were considered for inclusion. Eligible studies should have compared the maternal, perinatal and neonatal outcomes between pregnant women with gestational diabetes mellitus (GDM) managed by intermediate acting (NPH) and by long-acting insulin analogues. Statistical analysis was performed using STATA software. Results We found 17 studies to be eligible for inclusion. The mean gestational weight gain and risk of maternal hypoglycaemia, hypertensive disorder, caesarean delivery, spontaneous abortion, endometritis and wound infection or dehiscence were similar among pregnant women with GDM managed using long-acting insulin analogues and NPH. Those receiving long-acting insulin analogues had significantly lower HbA1c values in the second (WMD − .09, 95% CI 0.12, − 0.06; N = 4) and third trimester (WMD − 0.08, 95% CI − 0.14, − 0.02; N = 12). The mean gestational age and birth weight and risk of perinatal mortality, prematurity, large for gestational age, small for gestational age, shoulder dystocia and congenital abnormalities was similar among babies in both groups. No statistically significant differences in risk of admission to neonatal intensive care unit, respiratory distress, neonatal hypoglycaemia, 5 min APGAR score of < 7, neonatal hyperbilirubinemia and sepsis was observed. The quality of pooled evidence, as per GRADE criteria, was judged to be “very low” for all the maternal and neonatal outcomes considered. Conclusions Findings suggest no significant differences in the maternal, perinatal and neonatal outcomes between intermediate and long-acting insulin analogues. The results provide support for use of long-acting insulin analogues in women with GDM. However, evidence is still needed from high quality randomized controlled trials to arrive at a recommendation for inclusion in routine clinical care..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Diabetology & metabolic syndrome - 14(2022), 1 vom: 21. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jijiao [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Complications |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1186/s13098-022-00925-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051079887 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051079887 | ||
| 003 | DE-627 | ||
| 005 | 20230509114402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230508s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13098-022-00925-7 |2 doi | |
| 035 | |a (DE-627)SPR051079887 | ||
| 035 | |a (SPR)s13098-022-00925-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jijiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Maternal and neonatal outcomes with the use of long acting, compared to intermediate acting basal insulin (NPH) for managing diabetes during pregnancy: a systematic review and meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background To assess the impact of long-acting insulin analogues, compared to intermediate acting neutral protamine Hagedron (NPH), on maternal, perinatal and neonatal outcomes. Methods Studies for inclusion in the review were identified using a structured search strategy in PubMed, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) database. Studies that were randomized controlled trials or observational in design were considered for inclusion. Eligible studies should have compared the maternal, perinatal and neonatal outcomes between pregnant women with gestational diabetes mellitus (GDM) managed by intermediate acting (NPH) and by long-acting insulin analogues. Statistical analysis was performed using STATA software. Results We found 17 studies to be eligible for inclusion. The mean gestational weight gain and risk of maternal hypoglycaemia, hypertensive disorder, caesarean delivery, spontaneous abortion, endometritis and wound infection or dehiscence were similar among pregnant women with GDM managed using long-acting insulin analogues and NPH. Those receiving long-acting insulin analogues had significantly lower HbA1c values in the second (WMD − .09, 95% CI 0.12, − 0.06; N = 4) and third trimester (WMD − 0.08, 95% CI − 0.14, − 0.02; N = 12). The mean gestational age and birth weight and risk of perinatal mortality, prematurity, large for gestational age, small for gestational age, shoulder dystocia and congenital abnormalities was similar among babies in both groups. No statistically significant differences in risk of admission to neonatal intensive care unit, respiratory distress, neonatal hypoglycaemia, 5 min APGAR score of < 7, neonatal hyperbilirubinemia and sepsis was observed. The quality of pooled evidence, as per GRADE criteria, was judged to be “very low” for all the maternal and neonatal outcomes considered. Conclusions Findings suggest no significant differences in the maternal, perinatal and neonatal outcomes between intermediate and long-acting insulin analogues. The results provide support for use of long-acting insulin analogues in women with GDM. However, evidence is still needed from high quality randomized controlled trials to arrive at a recommendation for inclusion in routine clinical care. | ||
| 650 | 4 | |a Intermediate acting insulin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neutral protamine Hagedron |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NPH |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Long-acting insulin analogues |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Glargine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Detemir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Obstetric outcomes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neonatal outcomes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Complications |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Meta-analysis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ji, Xiaochen |4 aut | |
| 700 | 1 | |a Liu, Ting |4 aut | |
| 700 | 1 | |a Zhao, Nan |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetology & metabolic syndrome |d London : BioMed Central, 2009 |g 14(2022), 1 vom: 21. Okt. |w (DE-627)SPR030237963 |w (DE-600)2518786-7 |x 1758-5996 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:1 |g day:21 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13098-022-00925-7 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 1 |b 21 |c 10 | ||